argenx to Present at Upcoming Investor Conferences

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX) announced management's participation in several upcoming investor conferences. Key events include the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, JMP Securities Life Sciences Conference on June 16, J.P. Morgan European Healthcare Conference on June 17, and Raymond James Human Health Innovation Conference on June 22, 2021. The company focuses on developing treatments for severe autoimmune diseases and cancer, including efgartigimod and cusatuzumab.

June 1, 2021

Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in the following upcoming investor conferences:

• Goldman Sachs 42^nd Annual Global Healthcare Conference. Fireside chat on Tuesday, June 8, 2021 at 2:10 p.m. ET.
• JMP Securities Life Sciences Conference. Fireside chat on Wednesday, June 16, 2021 at 11:00 a.m. ET.
• J.P. Morgan European Healthcare Conference. Management will participate in investor meetings on Thursday, June 17, 2021.
• Raymond James Human Health Innovation Conference. Management will participate in a panel discussion on Tuesday, June 22, 2021 at 12:00 p.m. ET.

Additional information regarding these events will be available on the Company’s website at www.argenx.com.

About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit https://www.argenx.com/ and follow us on LinkedIn at https://www.linkedin.com/company/argenx/ and Twitter at https://twitter.com/argenxglobal.

For further information, please contact:

Media:

Kelsey Kirk
kkirk@argenx.com

Joke Comijn
jcomijn@argenx.com

Investors:

Beth DelGiacco
bdelgiacco@argenx.com

Michelle Greenblatt
mgreenblatt@argenx.com

FAQ

What investor conferences will argenx participate in June 2021?

argenx will participate in the Goldman Sachs Annual Global Healthcare Conference on June 8, JMP Securities Life Sciences Conference on June 16, J.P. Morgan European Healthcare Conference on June 17, and Raymond James Human Health Innovation Conference on June 22, 2021.

What time is the Goldman Sachs Conference for argenx?

The Goldman Sachs 42nd Annual Global Healthcare Conference fireside chat will take place on June 8, 2021, at 2:10 p.m. ET.

What is the focus of argenx as a company?

argenx is focused on developing innovative treatments for severe autoimmune diseases and cancer.

Who does argenx collaborate with on its drug development?

argenx collaborates with leading academic researchers and partners, including Janssen, for its drug development programs.

Where can I find more information about argenx's events?

Additional information on argenx's events can be found on the company's website at www.argenx.com.